



02-08-01

ACCO 3713

Express Mail No.: EL 501 636 830 US

RECEIPT
#3
S.B.
427-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jerome B. ZELDIS

Application No.: 09/734,460

Group Art Unit: 1614

Filed: December 11, 2000

Examiner: To Be Assigned

For: METHODS AND COMPOSITIONS
FOR THE PREVENTION AND
TREATMENT OF
ATHEROSCLEROSIS,
RESTENOSIS AND RELATED
DISORDERS

Attorney Docket No.: 9516-018

RECEIVED

APR 25 2001

TECH CENTER 1600/2000

REQUEST FOR CORRECTION OF FILING RECEIPT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant encloses the original filing receipt and a copy of the receipt indicating the necessary corrections in red ink in connection with the above-identified application. Please note that the official filing receipt contains a typographical error in the city of residence of the Applicant. Please correct the city of residence so that it reads "Princeton, NJ" instead of "Prinetone, NJ".

Please make the appropriate corrections and issue a corrected filing receipt. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date February 7, 2001


Anthony M. Insogna
Yann E. Pasquale Reg No. 35,203 *38,265*
Anthony M. Insogna (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures



UNITED STATES PATENT AND TRADEMARK OFFICE



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/734,460	12/11/2000 ✓	1614	1798	9516-018		42	15

20583
PENNIE AND EDMONDS
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 100362711

735BC

CONFIRMATION NO. 5112

FILING RECEIPT



OC000000005706168

Date Mailed: 01/25/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

✓ Jerome B. Zeldis, Princeton, NJ;

Princeton

Due 3/11/01

Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/170,820 12/15/1999

Foreign Applications

Projected Publication Date: To Be Determined - pending completion of Security Review

N n-Publication Request: No

Early Publication Request: No


** SMALL ENTITY **

Title

Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders

Preliminary Class

514



Data entry by : TADESSE, ETAGEAN

Team : OIPE

Date: 01/25/2001

LICENSE FOR FOREIGN FILING UNDER
Title 35, Unit d States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

FILE COPY

UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov


Bib Data Sheet

CONFIRMATION NO. 5112

SERIAL NUMBER 09/734,460	FILING DATE 12/11/2000 RULE	CLASS 514	GROUP ART UNIT 1614	ATTORNEY DOCKET NO. 9516-018
------------------------------------	---	---------------------	-------------------------------	--

APPLICANTS

Jerome B. Zeldis, Princeton, NJ; ✓

RECEIVED

** CONTINUING DATA *****

THIS APPLN CLAIMS BENEFIT OF 60/170,820 12/15/1999 ✓

APR 25 2001

TECH CENTER 1600/2900

** FOREIGN APPLICATIONS *****

** SMALL ENTITY **

Foreign Priority claimed 35 USC 119 (a-d) conditions met Verified and Acknowledged	<input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance	STATE OR COUNTRY NJ	SHEETS DRAWING	TOTAL CLAIMS 42	INDEPENDENT CLAIMS 15
Examiner's Signature <i>CLG</i> Initials					

ADDRESS

20583

TITLE

Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders ✓

FILING FEE RECEIVED 1798	FEES: Authority has been given in Paper. No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit